BACKGROUND: Long-term treatment with @entity1092 ( @entity2052 ) or @entity2049 ( @entity2050 ) may induce @entity4903 in @entity1 with @entity302 . METHODS: Serum concentrations of reproductive hormones were studied in 17 @entity1 and 22 @entity1 with recently diagnosed @entity302 before they started either @entity2052 or @entity2050 medication, @entity676 months later. RESULTS: No @entity1017 or clinical signs of hormonal disorders were observed during the follow-up. The mean serum levels of @entity251 , luteinizing hormone, follicle-stimulating hormone, and @entity443 ( @entity443 ) increased, and @entity9027 ( @entity2990 ) decreased, in @entity1 starting @entity2052 . Serum @entity251 levels increased in half of the @entity1 on @entity2052 . Serum concentrations of @entity1420 and @entity2494 increased, and gonadotropins decreased, in @entity1 on @entity2052 during the follow-up. Serum @entity443 levels increased and @entity2990 decreased during the first months of @entity2050 treatment in both sexes. In addition, the free- @entity342 index decreased in @entity1 after starting @entity2050 . CONCLUSIONS: Hormonal changes occur after only 1 month's use of @entity2052 or @entity2050 . @entity2052 -treatment seems to be associated with increased serum @entity342 levels, but the profile of hormonal changes appears to be different in @entity1 than in @entity1 . The use of @entity2050 , in turn, was associated with increased @entity443 concentrations and thus with diminished sex @entity134 function in both sexes. The @entity1 with increased serum @entity251 levels in the early phase of @entity2052 medication may be at increased risk for @entity2052 -related @entity4903 later during treatment.

Early hormonal changes during @entity1092 or XXXX treatment: a 3-month study.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity2990 :: ('CHEBI:16814', 'Chemical') :: ['DHEAS'] @entity2050 :: ('CHEBI:51097', 'Chemical') :: ['CBZ'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity2494 :: ('MESH:D003687', 'Chemical') :: ['dehydroepiandrosterone'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproate'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity2052 :: ('CHEBI:39867', 'Chemical') :: ['VPA'] @entity676 :: ('11169', 'Gene') :: ['and 1 and 3'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity9027 :: ('MESH:D019314', 'Chemical') :: ['dehydroepiandrosterone sulfate'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine'] @entity4903 :: ('MESH:D004700', 'Disease') :: ['reproductive endocrine disorders', 'endocrine disorders'] @entity443 :: ('6462', 'Gene') :: ['sex hormone-binding globulin', 'SHBG']
@entity2049 :: (MESH:D002220,Chemical) :: ['carbamazepine']
